The long-position on revive is still reflecting a possible $0.719 or higher by 2022-01 . The potential can reach significantly higher than $0.719 and may have the ability to reach $1.00 by 2022-06 . By 2025-12 , the potential can be as high as $3.00. However, there may be the potential for rapid spikes as high as $13.00 by 2026-02 . DISCLAIMER: THIS...
Sun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series Focus: Worldwide By Sun Storm Investment Research & NexGen Wealth Management Service A Profit & Solutions Strategy & Research Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures | USA |...
I've been following this particular stock since Feb of 2019. I am not very good at technical analysis but I know this stock should double on or before March 2021. With that assumption is their anyone that can chart this stock and come to the same conclusion? Thanks in advance.
This forecast is not financial advice . Please be responsible and speak with professional financial advisors. Please do your own research and create your own opinions . All comments below are also not financial advice. Markets can shift both up and down and down and up, so please be very careful.
Looking for a run in this tightly wound pattern. Usual 50:50 stop loss mgmt plan
Simple run back to 382, MA's have flipped. Looking for the bigger rally but may be too early in the large wedge pattern currently playing out. Daily 200 and top trend line may be the death of the trade. Usual stop loss management of move into profit the trail 50:50 weekly and daily.
I am already in from an earlier stage, but after breaking out of this triangle upwards I see RVVTF going up back to 75 cents around. It broke out of consolidation and came back down to re test, but after breaking past the sturdy resistance it is now on route up!
RVV looks like it came down highs before it step functioned to $0.75 then came back to the around $0.50 may be a decent entry when stock price goes below the dotted orange line...
There appears to be a " possible " (this is not a guarantee) positive repeat correction from around $0.3963 to $0.536 within the next 16 to 60 days . In the recent press releases there have been a lot of valuation placed heavily on the price $0.50. Please read the press releases for oneself and make up one's own mind on the perception of the purchases and...
Bullish Pennant Pros: Descending volume during formation 200MA ascending PPS above 50MA and 200MA R/R ratio above 16 250RSI above 50 RS Ascending and above 0 If confirmed: PT = 1.29$
Bullish Pennant Pros: Descending volume during formation 200MA ascending PPS above 50MA and 200MA R/R ratio above 4 Cons: 250RSI below 50 If confirmed: PT = 0,58$
For those who had taken profit or still waiting on the sidelines to get back into this bad boy, well here is your chance. We have just hit daily oversold conditions into an area of support and the rsi as crossed the 30 line. indicating a signal to go long. on the 65 minute timeframe we can also see a lot of bullish divergence. 0.240 would be a good target for a...
RVV is picking up some traction, one thing I notice about RVV is that the share price is directly correlated to the MACD indicator. You will see above that if you bought and the cross over to the upside, and sold at the crossover to the downside, you would be doing consistently well. RVV is presently crossing over to the upside, indicators are bullish....
Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, July 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...
UPDATE - Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19 www.globenewswire.com